Hepatitis B

Phase II clinical trial of ISS vaccine initiated

Published in Hepatitis Weekly, October 21st, 2002

Dynavax Technologies, a privately held biopharmaceutical company, announced it has initiated a phase II clinical study to evaluate the ability of its immunostimulatory DNA sequence (ISS) vaccine candidate to provide effective hepatitis B prophylaxis in patients after a single injection.

The study will compare the protective immune response of patients after immunization with either Engerix-B HBV vaccine, a commercially available hepatitis B vaccine, or recombinant hepatitis B surface antigen (rHBsAg) coadministered with Dynavax's proprietary immunostimulatory DNA sequences (1018-ISS). Infection with the hepatitis B virus (HBV) is a major global health problem, with 350...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-10-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry